Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.62
-3.06 (-1.25%)
AAPL  254.87
-3.40 (-1.32%)
AMD  252.55
+0.52 (0.21%)
BAC  51.70
-0.48 (-0.91%)
GOOG  333.25
-1.75 (-0.52%)
META  668.50
-4.48 (-0.66%)
MSFT  478.33
-2.25 (-0.47%)
NVDA  189.97
+1.45 (0.77%)
ORCL  172.22
-2.68 (-1.53%)
TSLA  433.07
+2.17 (0.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.